Alzheimer's Disease Drug Development: Research and Development Ecosystem

Alzheimer's Disease (AD) is a growing global public health challenge, and the development of new therapies is urgently needed. This book provides a comprehensive overview of the drug development ecosystem, emphasizing the contributions of each aspect in the pipeline. It covers topics such as non-clinical laboratory studies, biomarker development, artificial intelligence, clinical trial design, funding, and financing models. The approval of aducanumab has highlighted the critical role of the ecosystem in transferring an AD drug from discovery to regulatory review and marketing.

Format: Hardback
Length: 574 pages
Publication date: 31 March 2022
Publisher: Cambridge University Press

Alzheimer's Disease (AD) presents a rapidly escalating global public health concern, necessitating the immediate development of novel therapeutic interventions. A comprehensive network of organizations has emerged to expedite the discovery and development of drugs for AD. This book expertly compiles information on the drug development ecosystem, highlighting the contributions of each stage with a consistent chapter structure, facilitating swift access to relevant knowledge. The topics covered encompass non-clinical laboratory studies, biomarker development, artificial intelligence, clinical trial design and management, and funding and financing models. Additionally, the book delves into the crucial role of advocacy fundraising in drug development. The approval of aducanumab has shed light on the functioning of this ecosystem, providing a definitive account of how it facilitates the transition of an AD drug from its initial laboratory discovery to clinical trial testing, regulatory review, and eventual marketing.

Weight: 1340g
Dimension: 259 x 183 x 30 (mm)
ISBN-13: 9781108838665
Edition number: New ed